Optimal treatment strategy for central nervous system non-germinomatous germ cell tumors: A systematic review and meta-analysis

被引:0
|
作者
Zhou, Zhirui [1 ,2 ,7 ]
Zhang, Xiwei [3 ]
Zheng, Lin [4 ]
Yue, Qi [2 ,5 ]
Lin, Xin [6 ]
Wang, Yang [1 ,2 ,7 ]
Mao, Ying [2 ,5 ,8 ]
机构
[1] Fudan Univ, Huashan Hosp, Shanghai Med Coll, Radiat Oncol Ctr, 12 Urumchi Middle Rd, Shanghai 200040, Peoples R China
[2] Natl Ctr Neurol Disorders, Shanghai 200052, Peoples R China
[3] Fudan Univ, Jingan Dist Cent Hosp, Dept Oncol, Shanghai 200040, Peoples R China
[4] Taizhou Canc Hosp, Dept Radiat Oncol Ctr, Taizhou 317500, Zhejiang, Peoples R China
[5] Fudan Univ, Huashan Hosp, Shanghai Med Coll, Dept Neurosurg, 12 Urumchi Middle Rd, Shanghai 200040, Peoples R China
[6] Fudan Univ, Huashan Hosp, Shanghai Med Coll, Nursing Dept, Shanghai 200040, Peoples R China
[7] Fudan Univ, Huashan Hosp, Shanghai Med Coll, Radiat Oncol Ctr, Shanghai 200040, Peoples R China
[8] Natl Ctr Neurol Disorders, 958 Jinguang Rd, Shanghai 200052, Peoples R China
基金
中国国家自然科学基金;
关键词
Non-germinomatous germ cell tumors; Surgical resection; Radiotherapy; Chemotherapy; Meta-analysis; PHASE-II TRIAL; RADIATION-THERAPY; CHEMOTHERAPY; IRRADIATION; CHILDREN; SURGERY; RADIOTHERAPY; PROGNOSIS; OUTCOMES;
D O I
10.1016/j.critrevonc.2025.104615
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: To determine the optimal treatment modality for central nervous system (CNS) non-germinomatous germ cell tumors (NGGCTs).<br /> Materials and Methods: A search of Medline, Embase, Web of Science and Cochrane Library was conducted up to September 30, 2024. All studies were considered, covering all CNS NGGCT patients with an informative treatment approach. Pooled risk ratio (RR) and 95 % confidence interval (CI) were calculated.<br /> Results: Total 42 studies were included in the systematic review. Pooled risk ratio (RR) indicated a 28 % lower failure rate for the gross total resection (GTR) compared to the non-GTR group [RR = 0.72, 95% CI (0.55, 0.95), P = 0.02]. Meta-analysis showed that craniospinal irradiation (CSI) was associated with a significantly lower failure rate for localized NGGCTs [RR = 0.53, 95% CI (0.38, 0.74), P = 0.0002]. Meta-analysis manifested that the risk of any failure event was 27 % lower in the chemoradiotherapy group compared to radiotherapy alone [RR =0.73, 95% CI (0.55, 0.98), P = 0.04]. Total 21 studies reported treatment-related acute and/or late toxicity, combination chemotherapy increased acute toxic, and expanded RT field and/or dose mainly increased late toxicity.<br /> Conclusion: GTR was associated with better outcomes in terms of any failure event, and CSI was particularly beneficial for localized NGGCTs patients in reducing any failure event rate, and combination chemotherapy further reduced the failure risk. If CSI is combined with chemotherapy, the total RT dose can be appropriately reduced.
引用
收藏
页数:17
相关论文
共 50 条
  • [31] Multi-institutional analysis of central nervous system germ cell tumors in patients with Down syndrome
    Harris, Micah K.
    Graham, Richard T.
    Cappellano, Andrea M.
    Margol, Ashley S.
    Michaiel, George
    Crawford, John R.
    Ioakeim-Ioannidou, Myrsini
    Stanek, Joseph R.
    Liu, Kevin X.
    MacDonald, Shannon M.
    Abdelbaki, Mohamed S.
    PEDIATRIC BLOOD & CANCER, 2022, 69 (10)
  • [32] Germ cell tumors of the central nervous system: A brief review and site-specific considerations
    Marker, Daniel F.
    Pearce, Thomas M.
    SEMINARS IN DIAGNOSTIC PATHOLOGY, 2023, 40 (01) : 47 - 51
  • [33] Evaluating the Optimal Management of Inoperable Giant Cell Tumors of the Spine: A Systematic Review and Meta-Analysis
    Palmisciano, Paolo
    Ferini, Gianluca
    Chen, Andrew L.
    Balasubramanian, Kishore
    Kharbat, Abdurrahman F.
    Sagoo, Navraj S.
    Bin Alamer, Othman
    Scalia, Gianluca
    Umana, Giuseppe E.
    Aoun, Salah G.
    Haider, Ali S.
    CANCERS, 2022, 14 (04)
  • [34] Prognostic factors for patients with relapsed central nervous system nongerminomatous germ cell tumors
    Abu-Arja, Mohammad H.
    Osorio, Diana S.
    Lassaletta, Alvaro
    Graham, Richard T.
    Coven, Scott L.
    Stanek, Joseph R.
    Bouffet, Eric
    Finlay, Jonathan L.
    Abdelbaki, Mohamed S.
    PEDIATRIC BLOOD & CANCER, 2022, 69 (01)
  • [35] Medulloblastoma and central nervous system germ cell tumors in adults: is pediatric experience applicable?
    Mascarin, Maurizio
    Coassin, Elisa
    Franceschi, Enrico
    Gandola, Lorenza
    Carrabba, Giorgio
    Brandes, Alba A.
    Massimino, Maura
    CHILDS NERVOUS SYSTEM, 2019, 35 (12) : 2279 - 2287
  • [36] Intracranial non-germinomatous germ cell tumors in children and adolescents: how can the experience from an uppermiddle-income country contribute to the worldwide effort to improve outcomes?
    Cappellano, Andrea M.
    Dassi, Natalia
    Mancano, Bruna M.
    Epelman, Sidnei
    Almeida, Daniela B.
    Cavalheiro, Sergio
    Dastoli, Patricia A.
    Alves, Maria T. S.
    Nicacio, Jardel M.
    Costa, Marcos D. S.
    Silva, Frederico A.
    Aguiar, Simone S.
    Figueiredo, Maria L.
    Chen, Michael
    Silva, Nasjla S.
    Finlay, Jonathan L.
    FRONTIERS IN ONCOLOGY, 2024, 14
  • [37] Treatment of lacrimal gland adenoid cystic carcinoma: a systematic review and Meta-analysis
    Yan, Hai -Han
    Liu, Rui
    Wang, Nan
    Xu, Liang-Yuan
    Guo, Qi-Han
    Li, Jing
    Ma, Jian-Min
    INTERNATIONAL JOURNAL OF OPHTHALMOLOGY, 2024, 17 (01) : 164 - 172
  • [38] Clinical outcome of lymphadenectomy in malignant ovarian germ cell tumors: a systematic review and meta-analysis
    Han, Ling
    Chen, Yali
    Liu, Yana
    Zheng, Ai
    Chen, Hengxi
    AMERICAN JOURNAL OF CANCER RESEARCH, 2022, 12 (09): : 4458 - 4467
  • [39] Intracranial germ cell tumors in pediatric and adolescent patients in China: systematic review and meta-analysis
    Zhang, Anan
    Gao, Yijin
    PEDIATRIC MEDICINE, 2022, 5
  • [40] Monitoring pediatric CNS non-germinomatous germ cell tumors via cerebrospinal fluid circulating tumor DNA
    Zhang, Yu-Tong
    Jin, Xian-Mei
    Zhong, Xiao-Dan
    Chang, Jian
    PEDIATRIC BLOOD & CANCER, 2024,